Biomm (BIOM3.SA) Stock Price

Biomm Price

CLOSED
5.86
​
Market closed

Revenue has compounded at 21.5% per year over the past 19 years to 269.30 M BRL. Biomm's net margin stands at -2.5%, up from -74.9% several years earlier.

Biomm stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm business model & stock analysis

Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors.

Frequently asked questions about Biomm

Converted at the current exchange rate, the Biomm share trades at 0.94 EUR (5.86 BRL).

The revenue cannot currently be calculated for Biomm.

The profit cannot currently be calculated for Biomm.

The P/E ratio cannot be calculated for Biomm at the moment.

The P/S cannot be calculated for Biomm currently.

The Eulerpool Quality Score for Biomm is 4/10.

The ISIN of Biomm is BRBIOMACNOR2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Biomm is BIOM3.SA. The ticker symbol is used to trade Biomm shares on the stock exchange.

Fair ValueTerminal
6.04 BRL
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website biomm.com
Country
Brazil
Currency
BRL
Initial public offering
Sep 5, 2002
ISIN
BRBIOMACNOR2
Cusip
P1685G107
Market capitalization
801.88 M BRLSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
181.59
P/B Ratio
2.56
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.63 %
Last updated Nov 11, 2026, 6:02 AM

Biomm Peer Group

Biomm FIGI

BIOM3:BZ · BBG000P5NF01BIOM3:BS · BBG000P5NF92BIOM3:BN · BBG000P5NGT8

All fundamentals and in-depth analysis of Biomm

Our stock analysis for Biomm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.